Logo IQVIA

IQVIA (IQV) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
IQVIA · Health Care · ref. ETF XLV · 62 calls · price $260.68
💬JPI AI AssistantTry it →
What the company does: IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.

📈 IQVIA (IQV) stock price

$260.68+27.3% over range
Oct 14, 25low $156.66 · high $275.02Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
90% recommend buying · 10 analysts
📊 JPI status : IQVIA has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 IQV price target & analyst consensus — price $261

The price target · all analysts combined (10 targets)
Highest target · 1 firm of 10$329+26.2%
Median target · of 10 targets$287.5+10.3%
Lowest target · 2 firms of 10$270+3.6%
Current price$260.68
Where these 10 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 10100% $270 ↔ $329
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (240 calls tested). It aims for $270 (+3.6 %), call made on July 30, 2026, maturing on July 30, 2027 (76 d ago).

The 9 reliable analysts $287+10 %
The 1 other firm $319+22 %
How to read it: the 9 reliable firms are not filtered by optimism — 9 aim above the price, 0 below, hence their $287 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 10 ratings (last 6 months)
Strong Buy00%
Buy990%
Hold110%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about IQVIA? The JPI assistant answers using our backtest data.

📈 IQVIA fundamentals: valuation, margins & growth › open the full page

P/E 32.4Net margin 8.1 %Revenue growth +8.7 %High P/E

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 8 %
2023
Rev +4%Profit +24%
2024
Rev +3%Profit +1%
2025
Rev +6%Profit −1%

🔎 Detailed analyses

🏛️ Which US Congress members hold IQVIA (IQV)?

2 Congress members have disclosed IQV buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Susie Lee 3× · 43%Kevin Hern 3× · 48%
→ Full members ranking (who beats the market)

✅ Historical analyst reliability on IQV

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
SunTrust Robinson Humphrey 100% +69.1% 3
CFRA 100% +47.0% 2
Raymond James ↗ 100% +40.8% 2
B of A Securities ↗ 100% +38.0% 3
Wells Fargo ↗ 100% +32.8% 5
HSBC ↗ 100% +20.7% 2
Stephens & Co. ↗ 100% +10.7% 2
SVB Leerink 100% +4.3% 2
Baird ↗ 83% +20.2% 6
Citigroup ↗ 80% +30.2% 5
See the other 18 firms
Keybanc ↗ 20% -12.2% 5
Credit Suisse 20% +12.0% 5
Evercore ISI Group ↗ 38% -2.7% 8
Truist Securities ↗ 38% -1.4% 16
Deutsche Bank ↗ 38% +4.7% 8
Leerink Partners ↗ 50% -5.6% 2
BTIG ↗ 50% -3.2% 2
RBC Capital ↗ 50% -2.8% 6
Barclays ↗ 50% +2.2% 24
JP Morgan ↗ 50% +4.8% 8
Argus Research ↗ 50% +9.2% 4
Morgan Stanley ↗ 55% +9.0% 20
UBS ↗ 56% +11.5% 9
Mizuho ↗ 58% +5.9% 12
Goldman Sachs ↗ 67% +5.1% 3
Stifel ↗ 71% +28.7% 7
Guggenheim ↗ 75% +11.6% 4
Jefferies ↗ 75% +41.1% 4

📊 What $1,000 invested in IQVIA would be worth › open the full page

In short — $1,000 invested in IQVIA 10 years ago would be worth $2,814 today, i.e. +11%/yr on average. Best year: 2021 (+57%), worst: 2022 (-27%). Price performance, excluding dividends.

If I'd invested $1,000 in IQVIA

InvestmentWorth todayGain
1 years ago$983-2%
3 years ago$943-6%
5 years ago$1,078+8%
→ See IQVIA's full return history + gain calculator

Return by year (IQVIA)

YearReturn$1,000 invested at year start
2026 (YTD)-14%$857 (-14%)
2025+15%$983 (-2%)
2024-15%$835 (-16%)
→ See IQVIA's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on IQVIA

Loading news…

📋 All analyst calls on IQV

Mizuho ↗
Oct 7, 26
▲ Outperform · 🎯$300
Price at call : $258.88 — upside +16%
Today : $260.68 — upside +15%
🎯 on IQV : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Oct 7, 27
Barclays ↗
Oct 7, 26
▲ Overweight · 🎯$300
Price at call : $258.88 — upside +16%
Today : $260.68 — upside +15%
🎯 on IQV : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Oct 7, 27
RBC Capital ↗
Sep 29, 26
▲ Outperform · 🎯$319
Price at call : $268.99 — upside +19%
Today : $260.68 — upside +22%
🎯 on IQV : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Sep 29, 27
▲ Buy · 🎯$329
Price at call : $268.99 — upside +22%
Today : $260.68 — upside +26%
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Sep 28, 27
Morgan Stanley ↗
Sep 17, 26
■ Equal-Weight neutral · not a buy · 🎯$270
Price at call : $266.42 — gap to target +1%
Today : $260.68 — gap to target +4%
🎯 on IQV : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Sep 17, 27
JP Morgan ↗
Jul 29, 26
▲ Overweight · 🎯$285
Price at call : $237.79 — upside +20%
Today : $260.68 — upside +9%
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : Jul 29, 27
Stifel ↗
Jul 29, 26
▲ Buy · 🎯$276
Price at call : $237.79 — upside +16%
Today : $260.68 — upside +6%
🎯 on IQV : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Jul 29, 27
TD Cowen ↗
Jul 29, 26
▲ Buy · 🎯$288
Price at call : $237.79 — upside +21%
Today : $260.68 — upside +10%
🎯 on IQV : no call matured yet · 📊 on Health : 48% · +0.6% (98 calls)
in progress (365j)
matures : Jul 29, 27
See the other 54 calls, newest to oldest
RBC Capital ↗
Jul 29, 26
▲ Outperform · 🎯$247
Price at call : $237.79 — upside +4%
Today : $260.68 — upside -5%
🎯 on IQV : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Jul 29, 27
BMO Capital ↗
Jul 29, 26
▲ Outperform · 🎯$270
Price at call : $237.79 — upside +14%
Today : $260.68 — upside +4%
🎯 on IQV : no call matured yet · 📊 on Health : 60.4% · +8.8% (240 calls)
in progress (365j)
matures : Jul 29, 27
Baird ↗
Jul 29, 26
▲ Outperform · 🎯$287
Price at call : $247.56 — upside +16%
Today : $260.68 — upside +10%
🎯 on IQV : no call matured yet · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Jul 29, 27
Mizuho ↗
Jul 13, 26
▲ Outperform · 🎯$230
Price at call : $207.55 — upside +11%
Today : $260.68 — upside -12%
🎯 on IQV : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Jul 13, 27
Baird ↗
Jul 1, 26
▲ Outperform · 🎯$249
Price at call : $203.2 — upside +23%
Today : $260.68 — upside -4%
🎯 on IQV : no call matured yet · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Jul 1, 27
Morgan Stanley ↗
Jun 17, 26
■ Equal-Weight neutral · not a buy · 🎯$200
Price at call : $170.67 — gap to target +17%
Today : $260.68 — gap to target -23%
🎯 on IQV : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Jun 17, 27
▲ Outperform · 🎯$185
Price at call : $168.98 — upside +9%
Today : $260.68 — upside -29%
🎯 on IQV : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Apr 8, 27
TD Cowen ↗
Mar 9, 26
▲ Buy · 🎯$213
Price at call : $170.93 — upside +25%
Today : $260.68 — upside -18%
🎯 on IQV : no call matured yet · 📊 on Health : 48% · +0.6% (98 calls)
in progress (365j)
matures : Mar 9, 27
Barclays ↗
Mar 6, 26
▲ Overweight · 🎯$210
Price at call : $174.49 — upside +20%
Today : $260.68 — upside -19%
🎯 on IQV : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Mar 6, 27
RBC Capital ↗
Mar 3, 26
▲ Outperform · 🎯$221
Price at call : $177.88 — upside +24%
Today : $260.68 — upside -15%
🎯 on IQV : no call matured yet · 📊 on Health : 42.8% · -2.5% (397 calls)
in progress (365j)
matures : Mar 3, 27
▲ Buy · 🎯$245
Price at call : $165.62 — upside +48%
Today : $260.68 — upside -6%
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Feb 19, 27
JP Morgan ↗
Feb 6, 26
▲ Overweight · 🎯$225
Price at call : $192.67 — upside +17%
Today : $260.68 — upside -14%
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : Feb 6, 27
Citigroup ↗
Feb 6, 26
■ Neutral neutral · not a buy · 🎯$200
Price at call : $192.67 — gap to target +4%
Today : $260.68 — gap to target -23%
🎯 on IQV : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Feb 6, 27
UBS ↗
Feb 6, 26
▲ Buy · 🎯$240
Price at call : $192.67 — upside +25%
Today : $260.68 — upside -8%
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Feb 6, 27
Jefferies ↗
Feb 6, 26
▲ Buy · 🎯$255
Price at call : $192.67 — upside +32%
Today : $260.68 — upside -2%
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 51.2% · +4.7% (383 calls)
in progress (365j)
matures : Feb 6, 27
Stifel ↗
Feb 6, 26
▲ Buy · 🎯$220
Price at call : $192.67 — upside +14%
Today : $260.68 — upside -16%
🎯 on IQV : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Feb 6, 27
Barclays ↗
Feb 6, 26
■ Equal-Weight neutral · not a buy · 🎯$210
Price at call : $192.67 — gap to target +9%
Today : $260.68 — gap to target -19%
🎯 on IQV : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Feb 6, 27
TD Cowen ↗
Jan 22, 26
■ Hold neutral · not a buy · 🎯$245
Price at call : $235.31 — gap to target +4%
Today : $260.68 — gap to target -6%
🎯 on IQV : no call matured yet · 📊 on Health : 48% · +0.6% (98 calls)
in progress (365j)
matures : Jan 22, 27
▲ Buy · 🎯$290
Price at call : $242.41 — upside +20%
Today : $260.68 — upside +11%
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Jan 8, 27
UBS ↗
Jan 8, 26
▲ Buy · 🎯$280
Price at call : $242.41 — upside +16%
Today : $260.68 — upside +7%
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Jan 8, 27
▲ Overweight · 🎯$265
Price at call : $227.24 — upside +17%
Today : $260.68 — upside +2%
🎯 on IQV : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)
in progress (365j)
matures : Dec 2, 26
BMO Capital ↗
Nov 13, 25
▲ Outperform · 🎯$260
Price at call : $223.55 — upside +16%
Today : $260.68 — upside -0%
🎯 on IQV : no call matured yet · 📊 on Health : 60.4% · +8.8% (240 calls)
in progress (365j)
matures : Nov 13, 26
TD Cowen ↗
Nov 3, 25
■ Hold neutral · not a buy · 🎯$215
Price at call : $210.96 — gap to target +2%
Today : $260.68 — gap to target -18%
🎯 on IQV : no call matured yet · 📊 on Health : 48% · +0.6% (98 calls)
in progress (365j)
matures : Nov 3, 26
Citigroup ↗
Oct 29, 25
■ Neutral neutral · not a buy · 🎯$230
Price at call : $216.47 — gap to target +6%
Today : $260.68 — gap to target -12%
🎯 on IQV : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Oct 29, 26
UBS ↗
Oct 29, 25
▲ Buy · 🎯$250
Price at call : $216.47 — upside +15%
Today : $260.68 — upside -4%
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Oct 29, 26
Stifel ↗
Oct 29, 25
▲ Buy · 🎯$254
Price at call : $216.47 — upside +17%
Today : $260.68 — upside -3%
🎯 on IQV : no call matured yet · 📊 on Health : 50.7% · +7.8% (304 calls)
in progress (365j)
matures : Oct 29, 26
▲ Buy · 🎯$265
Price at call : $216.47 — upside +22%
Today : $260.68 — upside +2%
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Oct 29, 26
JP Morgan ↗
Oct 29, 25
▲ Overweight · 🎯$255
Price at call : $216.47 — upside +18%
Today : $260.68 — upside -2%
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : Oct 29, 26
Baird ↗
Oct 29, 25
▲ Outperform · 🎯$258
Price at call : $217.83 — upside +18%
Today : $260.68 — upside -1%
🎯 on IQV : no call matured yet · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Oct 29, 26
HSBC ↗
Oct 9, 25
▲ Buy · 🎯$235
Price at call : $203 — upside +16%
Today : $260.68 — upside -10%
Expected +16% · Actual +28% · Reason (≥ +15%) : ✓ Yes
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 55.2% · +1.7% (29 calls)
+28.0%
stock +28% · XLV +18%
matured Oct 9, 26
▲ Outperform · 🎯$240
Price at call : $200.6 — upside +20%
Today : $260.68 — upside -8%
Expected +20% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on IQV : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
+29.0%
stock +29% · XLV +16%
matured Oct 8, 26
Barclays ↗
Oct 2, 25
■ Equal-Weight neutral · not a buy · 🎯$200
Price at call : $206.63 — gap to target -3%
Today : $260.68 — gap to target -23%
🎯 on IQV : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Oct 2, 26
Jefferies ↗
Sep 9, 25
▲ Buy · 🎯$225
Price at call : $189.64 — upside +19%
Today : $260.68 — upside -14%
Expected +19% · Actual +36% · Reason (≥ +15%) : ✓ Yes
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 51.2% · +4.7% (383 calls)
+35.5%
stock +36% · XLV +20%
matured Sep 9, 26
Mizuho ↗
Jul 25, 25
▲ Outperform · 🎯$225
Price at call : $197.76 — upside +14%
Today : $260.68 — upside -14%
Expected +14% · Actual +8% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
+7.8%
stock +8% · XLV +21%
matured Jul 25, 26
Citigroup ↗
Jul 23, 25
■ Neutral neutral · not a buy · 🎯$200
Price at call : $200.82 — gap to target -0%
Today : $260.68 — gap to target -23%
🎯 on IQV : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Jul 23, 26
UBS ↗
Jul 23, 25
▲ Buy · 🎯$225
Price at call : $200.82 — upside +12%
Today : $260.68 — upside -14%
Expected +12% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 51.7% · +3.1% (358 calls)
+3.6%
stock +4% · XLV +20%
matured Jul 23, 26
▲ Buy · 🎯$235
Price at call : $200.82 — upside +17%
Today : $260.68 — upside -10%
Expected +17% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
+3.6%
stock +4% · XLV +20%
matured Jul 23, 26
Barclays ↗
Jul 23, 25
■ Equal-Weight neutral · not a buy · 🎯$185
Price at call : $194.24 — gap to target -5%
Today : $260.68 — gap to target -29%
🎯 on IQV : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Jul 23, 26
Baird ↗
Jul 23, 25
■ Neutral neutral · not a buy · 🎯$196
Price at call : $194.24 — gap to target +1%
Today : $260.68 — gap to target -25%
🎯 on IQV : no call matured yet · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Jul 23, 26
▲ Outperform · 🎯$180
Price at call : $162.02 — upside +11%
Today : $260.68 — upside -31%
Expected +11% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on IQV : 100% (2 calls matureds) · 📊 on Health : 44.6% · -0.4% (186 calls)
+29.0%
stock +29% · XLV +20%
matured Jul 9, 26
JP Morgan ↗
May 19, 25
▲ Overweight · 🎯$177
Price at call : $144.95 — upside +22%
Today : $260.68 — upside -32%
Expected +22% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 53.8% · +5.2% (364 calls)
+18.3%
stock +18% · XLV +9%
matured May 19, 26
Mizuho ↗
May 15, 25
▲ Outperform · 🎯$190
Price at call : $142.82 — upside +33%
Today : $260.68 — upside -27%
Expected +33% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on IQV : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
+21.0%
stock +21% · XLV +9%
matured May 15, 26
▲ Buy · 🎯$216
Price at call : $143.22 — upside +51%
Today : $260.68 — upside -17%
Expected +51% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
+16.8%
stock +17% · XLV +9%
matured Apr 10, 26
▲ Buy · 🎯$263
Price at call : $206.97 — upside +27%
Today : $260.68 — upside +1%
Expected +27% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
-11.8%
stock -12% · XLV +6%
matured Feb 10, 26
▲ Buy · 🎯$261
Price at call : $199.06 — upside +31%
Today : $260.68 — upside +0%
Expected +31% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
+12.3%
stock +12% · XLV +11%
matured Dec 12, 25
▲ Outperform · 🎯$248
Price at call : $194.38 — upside +28%
Today : $260.68 — upside -5%
Expected +28% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 100% (1 call matured) · 📊 on Health : 53.7% · -6.2% (41 calls)
+11.7%
stock +12% · XLV +6%
matured Nov 19, 25
▲ Buy · 🎯$265
Price at call : $212.87 — upside +24%
Today : $260.68 — upside +2%
Expected +24% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
-1.3%
stock -1% · XLV -1%
matured Nov 4, 25
▲ Buy · 🎯$286
Price at call : $232.98 — upside +23%
Today : $260.68 — upside +10%
Expected +23% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
-12.8%
stock -13% · XLV -7%
matured Oct 14, 25
▲ Buy · 🎯$300
Price at call : $238.75 — upside +26%
Today : $260.68 — upside +15%
Expected +26% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
-15.9%
stock -16% · XLV -9%
matured Jul 23, 25
▲ Buy · 🎯$292
Price at call : $227.04 — upside +29%
Today : $260.68 — upside +12%
Expected +29% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
-32.9%
stock -33% · XLV -2%
matured May 3, 25
▲ Buy · 🎯$297
Price at call : $248.84 — upside +19%
Today : $260.68 — upside +14%
Expected +19% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
-23.3%
stock -23% · XLV +1%
matured Feb 26, 25
▲ Buy · 🎯$286
Price at call : $220.52 — upside +30%
Today : $260.68 — upside +10%
Expected +30% · Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
-9.6%
stock -10% · XLV -0%
matured Jan 3, 25
▲ Buy · 🎯$240
Price at call : $209.52 — upside +15%
Today : $260.68 — upside -8%
Expected +15% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
-5.7%
stock -6% · XLV +10%
matured Nov 20, 24
▲ Buy · 🎯$260
Price at call : $196.43 — upside +32%
Today : $260.68 — upside -0%
Expected +32% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on IQV : 33% (12 calls matureds) · 📊 on Health : 49.4% · +2.3% (263 calls)
+15.8%
stock +16% · XLV +18%
matured Oct 2, 24

Frequently asked questions

Should I buy IQVIA stock?

This isn't buy advice. For IQVIA, the analyst consensus is "Buy", with an average price target of $288 (+10% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (3 calls tracked on IQVIA). We show the numbers — you decide.

Is it too late to buy IQVIA? How high can it go?

The most bullish analyst target on IQVIA is $329 (+26% above today's price); the average is $288. That's the upside they see. Check how reliable those analysts have actually been on IQVIA on our site before trusting it.

Is IQVIA still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 28 analysts have a real record on IQVIA, the best hitting 100% over 3 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in IQVIA? The case for and against

The arguments for and against, one by one, from the numbers: why invest in IQV (and why hesitate).

What has IQVIA's past performance been?

Historical returns and a "how much if I had invested" calculator: IQV performance & returns.

What is the best month to buy IQV?

The 12 months ranked by the stock's past returns: best & worst month to buy IQV.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)